Haya Therapeutics
5 known investors
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
Founders & leadership
Investors · 5
Founder mafia
2 people who came through Haya Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Haya Therapeutics do?
- HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
- Who founded Haya Therapeutics?
- Haya Therapeutics was founded by Samir Ounzain, Daniel Blessing.
- Who are Haya Therapeutics's investors?
- Haya Therapeutics's investors include Broadview Ventures, Sofinnova Partners, Apollo Health Ventures, +ND Capital, 4see Ventures.